Octapharma launches phase 3 superiority study for PANS
This article was originally published here
PANS is a condition defined by sudden onset of obsessive-compulsive symptoms and/or severe eating restrictions, along with at least two other cognitive, behavioral, or neurological symptoms, according to
The post Octapharma launches phase 3 superiority study for PANS appeared first on Pharmaceutical Business review.
Leave a Reply
Want to join the discussion?Feel free to contribute!